Coherus BioSciences, Inc(NASDAQ:CHRS) 
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline...
Website: http://www.coherus.com
Founded: 2010
Full Time Employees: 306
Sector: Healthcare
Industry: Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
net revenue | 12,310,000 | 12,748,000 | 11,571,000 | 10,254,000 | 7,599,000 | 54,144,000 | 70,774,000 | 64,979,000 | 77,063,000 | 91,524,000 | 74,568,000 | 58,716,000 | 32,436,000 | 45,352,000 | 45,424,000 | 60,151,000 | 60,115,000 | ||||||||||||||||||||||||||||||
yoy | 61.99% | -76.46% | -83.65% | -84.22% | -90.14% | -40.84% | -5.09% | 10.67% | 137.58% | 101.81% | 64.16% | -2.39% | -46.04% | ||||||||||||||||||||||||||||||||||
qoq | -3.44% | 10.17% | 12.84% | 34.94% | -85.97% | -23.50% | 8.92% | -15.68% | -15.80% | 22.74% | 27.00% | 81.02% | -28.48% | -0.16% | -24.48% | 0.06% | |||||||||||||||||||||||||||||||
costs and expenses: | |||||||||||||||||||||||||||||||||||||||||||||||
cost of goods sold | 3,814,000 | 4,045,000 | 3,721,000 | 3,395,000 | 2,653,000 | 33,858,000 | 20,741,000 | 28,368,000 | 34,586,000 | 84,567,000 | 32,703,000 | 24,848,000 | 16,874,000 | 14,202,000 | 35,234,000 | 11,277,000 | 9,370,000 | 12,104,000 | 21,280,000 | 16,696,000 | 7,511,000 | 11,673,000 | 9,000,000 | 10,139,000 | 6,855,000 | 7,805,000 | 6,447,000 | 601,000 | 2,225,000 | ||||||||||||||||||
research and development | 21,543,000 | 30,974,000 | 27,252,000 | 26,306,000 | 24,356,000 | 21,235,000 | 21,676,000 | 21,955,000 | 28,470,000 | 26,368,000 | 25,647,000 | 23,267,000 | 34,154,000 | 29,022,000 | 45,808,000 | 41,611,000 | 82,917,000 | 50,762,000 | 54,085,000 | 54,766,000 | 203,492,000 | 44,628,000 | 38,851,000 | 26,173,000 | 33,107,000 | 34,948,000 | 21,568,000 | 18,883,000 | 18,789,000 | 26,662,000 | 31,603,000 | 26,519,000 | 25,455,000 | 31,488,000 | 42,626,000 | 34,500,000 | 53,775,000 | 59,010,000 | 64,573,000 | 65,544,000 | 65,313,000 | 51,433,000 | 68,218,000 | 56,944,000 | 36,467,000 | 26,867,000 | 18,496,000 |
selling, general and administrative | 23,104,000 | 23,609,000 | 24,931,000 | 26,039,000 | 26,025,000 | 41,297,000 | 34,744,000 | 35,165,000 | 56,532,000 | 49,494,000 | 48,224,000 | 45,144,000 | 49,153,000 | 53,621,000 | 44,831,000 | 51,276,000 | 48,753,000 | 50,052,000 | 39,925,000 | 40,345,000 | 39,391,000 | 37,693,000 | 31,984,000 | 34,052,000 | 35,350,000 | 36,070,000 | 31,828,000 | 36,456,000 | 32,683,000 | ||||||||||||||||||
total costs and expenses | 48,461,000 | 58,628,000 | 55,904,000 | 55,740,000 | 53,034,000 | 96,390,000 | 77,161,000 | 85,488,000 | 119,588,000 | 160,429,000 | 106,574,000 | 93,259,000 | 100,181,000 | 96,845,000 | 125,873,000 | 104,164,000 | 141,040,000 | ||||||||||||||||||||||||||||||
income from operations | -36,151,000 | -45,880,000 | -44,333,000 | -45,486,000 | -45,435,000 | -42,246,000 | -6,387,000 | -20,509,000 | -42,525,000 | -68,905,000 | -32,006,000 | -34,543,000 | -67,745,000 | -51,493,000 | -80,449,000 | -44,013,000 | -80,925,000 | -39,547,000 | -32,787,000 | -24,164,000 | -167,360,000 | 16,425,000 | 33,716,000 | 65,310,000 | 40,868,000 | 45,033,000 | 51,841,000 | 27,493,000 | -16,599,000 | -60,502,000 | -56,972,000 | -44,910,000 | -42,032,000 | -46,466,000 | -56,615,000 | -56,638,000 | -72,417,000 | -73,460,000 | 84,617,000 | -62,736,000 | -64,352,000 | -52,207,000 | -71,217,000 | -58,895,000 | -36,748,000 | -26,560,000 | -6,423,000 |
yoy | -20.43% | 8.60% | 594.11% | 121.79% | 6.84% | -38.69% | -80.04% | -40.63% | -37.23% | 33.81% | -60.22% | -21.52% | -16.29% | 30.21% | 145.37% | 82.14% | -51.65% | -340.77% | -197.24% | -137.00% | -509.51% | -63.53% | -34.96% | 137.55% | -346.21% | -174.43% | -190.99% | -161.22% | -60.51% | 30.21% | 0.63% | -20.71% | -41.96% | -36.75% | -166.91% | -9.72% | 12.53% | 40.71% | -218.82% | 6.52% | 75.12% | 96.56% | 1008.78% | ||||
qoq | -21.21% | 3.49% | -2.53% | 0.11% | 7.55% | 561.44% | -68.86% | -51.77% | -38.28% | 115.29% | -7.34% | -49.01% | 31.56% | -35.99% | 82.78% | -45.61% | 104.63% | 20.62% | 35.69% | -85.56% | -1118.93% | -51.28% | -48.38% | 59.81% | -9.25% | -13.13% | 88.56% | -265.63% | -72.56% | 6.20% | 26.86% | 6.85% | -9.54% | -17.93% | -0.04% | -21.79% | -1.42% | -186.81% | -234.88% | -2.51% | 23.26% | -26.69% | 20.92% | 60.27% | 38.36% | 313.51% | |
operating margin % | -293.67% | -359.90% | -383.14% | -443.59% | -597.91% | -78.03% | -9.02% | -31.56% | -55.18% | -75.29% | -42.92% | -58.83% | -208.86% | -113.54% | -177.11% | -73.17% | -134.62% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% |
interest expense | -2,186,000 | -2,249,000 | -2,325,000 | -2,277,000 | -2,150,000 | -5,346,000 | -5,362,000 | -5,334,000 | -11,116,000 | -10,619,000 | -10,268,000 | -9,943,000 | -9,712,000 | -9,385,000 | -7,540,000 | -6,580,000 | -8,969,000 | -5,793,000 | -5,771,000 | -5,747,000 | -5,648,000 | -5,671,000 | -5,656,000 | -5,408,000 | -4,431,000 | -4,483,000 | -4,469,000 | -4,433,000 | -4,216,000 | -2,434,000 | -2,425,000 | -2,417,000 | -2,408,000 | -2,400,000 | -2,392,000 | -2,384,000 | -2,376,000 | -2,369,000 | -2,420,000 | -2,354,000 | -837,000 | -33,000 | -1,000 | ||||
other income | 1,402,000 | 1,782,000 | 2,141,000 | 2,901,000 | 187,000 | -3,047,000 | 2,084,000 | 1,467,000 | 2,869,000 | -129,000 | 2,253,000 | 1,617,000 | 1,728,000 | 2,008,000 | 1,339,000 | 443,000 | 32,000 | -385,000 | 30,000 | 11,000 | 61,000 | 6,000 | 56,000 | 423,000 | 68,000 | 721,000 | 518,000 | 558,000 | 811,000 | 340,000 | 571,000 | 3,642,000 | 138,000 | -203,000 | 14,000 | 3,620,000 | -940,500 | 1,647,000 | |||||||||
loss from continuing operations before income taxes | -36,935,000 | -46,347,000 | -44,517,000 | -44,862,000 | -47,398,000 | ||||||||||||||||||||||||||||||||||||||||||
income tax provision | -380,000 | 1,052,000 | 183,000 | 1,294,000 | 933,000 | 2,044,000 | 847,000 | 51,000 | |||||||||||||||||||||||||||||||||||||||
net income from continuing operations | -36,935,000 | -46,347,000 | -44,517,000 | -44,862,000 | -47,398,000 | ||||||||||||||||||||||||||||||||||||||||||
net loss from discontinued operations, net of tax | -1,392,000 | ||||||||||||||||||||||||||||||||||||||||||||||
net income | -38,327,000 | -37,643,000 | -35,531,000 | 297,767,000 | -56,569,000 | -50,696,000 | -10,751,000 | -12,921,000 | 102,875,000 | -79,653,000 | -39,641,000 | -42,869,000 | -75,729,000 | -58,870,000 | -86,650,000 | -50,150,000 | -96,084,000 | -45,725,000 | -38,528,000 | -29,900,000 | -172,947,000 | 9,708,000 | 27,933,000 | 59,031,000 | 35,572,000 | 39,227,000 | 47,043,000 | 23,567,000 | -20,004,000 | -62,596,000 | -58,826,000 | -43,685,000 | -44,302,000 | -49,069,000 | -58,993,000 | -55,402,000 | -74,822,000 | -75,944,000 | 83,844,000 | -70,150,000 | -65,538,000 | -52,580,000 | -71,485,000 | -59,034,000 | -40,839,000 | -29,023,000 | -7,914,000 |
yoy | -32.25% | -25.75% | 230.49% | -2404.52% | -154.99% | -36.35% | -72.88% | -69.86% | -235.85% | 35.30% | -54.25% | -14.52% | -21.18% | 28.75% | 124.90% | 67.73% | -44.44% | -571.00% | -237.93% | -150.65% | -586.19% | -75.25% | -40.62% | 150.48% | -277.82% | -162.67% | -179.97% | -153.95% | -54.85% | 27.57% | -0.28% | -21.15% | -40.79% | -35.39% | -170.36% | -21.02% | 14.17% | 44.44% | -217.29% | 18.83% | 60.48% | 81.17% | 803.27% | ||||
qoq | 1.82% | 5.94% | -111.93% | -626.38% | 11.58% | 371.55% | -16.79% | -112.56% | -229.15% | 100.94% | -7.53% | -43.39% | 28.64% | -32.06% | 72.78% | -47.81% | 110.13% | 18.68% | 28.86% | -82.71% | -1881.49% | -65.25% | -52.68% | 65.95% | -9.32% | -16.61% | 99.61% | -217.81% | -68.04% | 6.41% | 34.66% | -1.39% | -9.71% | -16.82% | 6.48% | -25.95% | -1.48% | -190.58% | -219.52% | 7.04% | 24.64% | -26.45% | 21.09% | 44.55% | 40.71% | 266.73% | |
net income margin % | -311.35% | -295.29% | -307.07% | 2903.91% | -744.43% | -93.63% | -15.19% | -19.88% | 133.49% | -87.03% | -53.16% | -73.01% | -233.47% | -129.81% | -190.76% | -83.37% | -159.83% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% |
net income per share | -0.27 | -0.34 | -0.31 | 2.57 | -0.49 | -0.29 | -0.83 | -0.87 | -0.68 | -0.74 | -1.08 | -1.54 | -1.72 | -1.67 | -1.33 | -1.86 | -1.56 | -1.22 | 2.98 | -1.79 | |||||||||||||||||||||||||||
weighted-average number of shares used in computing net loss per share: | |||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | 136,398,303 | 117,143,457 | 116,229,170 | 116,077,710 | 115,857,780 | ||||||||||||||||||||||||||||||||||||||||||
comprehensive loss: | |||||||||||||||||||||||||||||||||||||||||||||||
other comprehensive loss: | |||||||||||||||||||||||||||||||||||||||||||||||
unrealized loss on available-for-sale securities, net of tax | -73 | ||||||||||||||||||||||||||||||||||||||||||||||
comprehensive loss | -38,400 | ||||||||||||||||||||||||||||||||||||||||||||||
loss on debt extinguishment | -12,630,000 | -6,222,000 | |||||||||||||||||||||||||||||||||||||||||||||
net income from discontinued operations, net of tax | 8,704,000 | 8,986,000 | 342,629,000 | -9,171,000 | |||||||||||||||||||||||||||||||||||||||||||
net loss from continuing operations - basic and diluted | -0.38 | -0.38 | -0.39 | -0.41 | |||||||||||||||||||||||||||||||||||||||||||
net income from discontinued operations - basic and diluted | 0.05 | 0.08 | 2.95 | -0.08 | |||||||||||||||||||||||||||||||||||||||||||
weighted-average number of shares used in computing net income per share: | |||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | 136,398,303 | 117,143,457 | 116,229,170 | 116,077,710 | 115,857,780 | ||||||||||||||||||||||||||||||||||||||||||
gain on sale transactions | -57,000 | -1,086,000 | 24,085,000 | ||||||||||||||||||||||||||||||||||||||||||||
income before income taxes | -50,696,000 | -10,751,000 | -12,921,000 | 102,875,000 | -79,653,000 | -40,021,000 | -42,869,000 | -75,729,000 | -58,870,000 | -86,650,000 | -50,150,000 | ||||||||||||||||||||||||||||||||||||
net income per share | -0.27 | -0.34 | -0.31 | 2.57 | -0.49 | -0.29 | -0.83 | -0.87 | -0.68 | -0.74 | -1.08 | -1.54 | -1.72 | -1.67 | -1.33 | -1.86 | -1.56 | -1.22 | 2.98 | -1.79 | |||||||||||||||||||||||||||
basic | -0.44 | -0.09 | -0.11 | 0.91 | -0.59 | -0.49 | -0.4 | -2.37 | 0.13 | 0.39 | 0.83 | 0.5 | 0.56 | 0.67 | 0.34 | -0.92 | -1.09 | -0.313 | 1.93 | ||||||||||||||||||||||||||||
diluted | -0.4 | -0.09 | -0.11 | 0.83 | -0.59 | -0.49 | -0.4 | -2.37 | 0.1 | 0.33 | 0.7 | 0.48 | 0.54 | 0.63 | 0.32 | -0.92 | -1.09 | -0.313 | 1.67 | ||||||||||||||||||||||||||||
weighted-average number of shares used in computing net income per share: | |||||||||||||||||||||||||||||||||||||||||||||||
basic | 114,553,537 | 115,210,091 | 114,819,965 | 112,749,306 | 77,630,020 | 75,449,632 | 79,013,240 | 75,559,697 | 72,832,953 | 71,411,705 | 71,649,350 | 71,099,773 | 70,662,185 | 69,679,916 | 69,877,693 | 69,479,016 | 54,070,872 | 43,469,986 | |||||||||||||||||||||||||||||
diluted | 114,830,462 | 115,210,091 | 114,819,965 | 125,529,971 | 77,630,020 | 75,449,632 | 79,013,240 | 75,559,697 | 72,832,953 | 83,491,898 | 87,470,337 | 88,660,280 | 74,416,554 | 73,185,943 | 78,530,227 | 72,963,972 | 54,070,872 | 51,581,298 | |||||||||||||||||||||||||||||
gain on sale transaction | 153,647,000 | ||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted net loss per share | -0.74 | -0.41 | -0.49 | -0.96 | -0.75 | -1.11 | -0.65 | -1.24 | |||||||||||||||||||||||||||||||||||||||
weighted-average number of shares used in computing basic and diluted net loss per share | 94,162,637 | 97,738,509 | 87,269,614 | 79,268,853 | 77,746,895 | 77,554,717 | 77,253,699 | ||||||||||||||||||||||||||||||||||||||||
net loss before income taxes | -96,084,000 | ||||||||||||||||||||||||||||||||||||||||||||||
revenue: | |||||||||||||||||||||||||||||||||||||||||||||||
net product revenue | 63,295,000 | 82,503,000 | 87,643,000 | 83,034,000 | 110,419,000 | 113,551,000 | 135,674,000 | 116,180,000 | 123,856,000 | 111,684,000 | 83,433,000 | 37,098,000 | |||||||||||||||||||||||||||||||||||
cost and expenses: | |||||||||||||||||||||||||||||||||||||||||||||||
total cost and expenses | 112,918,000 | 115,290,000 | |||||||||||||||||||||||||||||||||||||||||||||
net income before income taxes | -45,725,000 | -38,528,000 | -29,900,000 | -172,947,000 | 10,760,000 | 28,116,000 | 60,325,000 | 36,505,000 | 41,271,000 | 47,890,000 | 23,618,000 | ||||||||||||||||||||||||||||||||||||
operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||
total operating expenses | 111,807,000 | 250,394,000 | 93,994,000 | 79,835,000 | 70,364,000 | 75,312,000 | 78,823,000 | 59,843,000 | 55,940,000 | 53,697,000 | 60,502,000 | 56,972,000 | 44,910,000 | 42,032,000 | 46,466,000 | 56,615,000 | 58,033,000 | 72,578,000 | 74,304,000 | 78,218,000 | 76,804,000 | 76,711,000 | 62,405,000 | 78,384,000 | 65,761,000 | 42,558,000 | 33,053,000 | 22,475,000 | |||||||||||||||||||
net loss attributable to non-controlling interest | 18,000 | 47,000 | 5,000 | 2,000 | 4,000 | 66,000 | 44,000 | 23,000 | 95,000 | 183,000 | 150,000 | 189,000 | 151,000 | 224,000 | 114,000 | -111,000 | 42,000 | ||||||||||||||||||||||||||||||
net income attributable to coherus | 39,227,000 | 47,043,000 | 23,567,000 | -47,275,750 | -58,989,000 | -12,854,000 | 83,939,000 | ||||||||||||||||||||||||||||||||||||||||
weighted-average number of shares used in computing net income per share attributable to coherus: | |||||||||||||||||||||||||||||||||||||||||||||||
basic | 114,553,537 | 115,210,091 | 114,819,965 | 112,749,306 | 77,630,020 | 75,449,632 | 79,013,240 | 75,559,697 | 72,832,953 | 71,411,705 | 71,649,350 | 71,099,773 | 70,662,185 | 69,679,916 | 69,877,693 | 69,479,016 | 54,070,872 | 43,469,986 | |||||||||||||||||||||||||||||
diluted | 114,830,462 | 115,210,091 | 114,819,965 | 125,529,971 | 77,630,020 | 75,449,632 | 79,013,240 | 75,559,697 | 72,832,953 | 83,491,898 | 87,470,337 | 88,660,280 | 74,416,554 | 73,185,943 | 78,530,227 | 72,963,972 | 54,070,872 | 51,581,298 | |||||||||||||||||||||||||||||
net loss attributable to coherus | -20,004,000 | -62,596,000 | -58,808,000 | -43,638,000 | -44,297,000 | -55,336,000 | -74,778,000 | -69,967,000 | -65,388,000 | -52,391,000 | -71,334,000 | -58,810,000 | -40,725,000 | -29,134,000 | -7,872,000 | ||||||||||||||||||||||||||||||||
weighted-average number of shares used in computing net loss per share attributable to coherus, basic and diluted | 69,140,697 | 65,034,827 | 67,848,730 | 63,960,567 | 60,122,050 | 53,133,620 | 51,291,787 | 48,711,958 | 41,912,300 | 40,698,309 | 39,095,975 | 37,122,008 | 38,426,734 | 37,672,748 | 33,377,298 | 8,186,529 | 4,409,703 | ||||||||||||||||||||||||||||||
collaboration and license revenue | 1,395,000 | 161,000 | 214,000 | 162,835,000 | 14,068,000 | 12,359,000 | 10,198,000 | 7,167,000 | 6,866,000 | 5,810,000 | 5,313,000 | 15,620,000 | |||||||||||||||||||||||||||||||||||
general and administrative | 15,084,250 | 25,369,000 | 18,391,000 | 16,577,000 | 14,978,000 | 13,989,000 | 23,533,000 | 18,803,000 | 15,294,000 | 13,645,000 | 11,260,000 | 11,398,000 | 10,972,000 | 10,166,000 | 8,817,000 | 6,091,000 | 6,186,000 | 3,979,000 | |||||||||||||||||||||||||||||
weighted-average number of shares used in computing net income (loss) per share attributable to coherus | |||||||||||||||||||||||||||||||||||||||||||||||
basic | 114,553,537 | 115,210,091 | 114,819,965 | 112,749,306 | 77,630,020 | 75,449,632 | 79,013,240 | 75,559,697 | 72,832,953 | 71,411,705 | 71,649,350 | 71,099,773 | 70,662,185 | 69,679,916 | 69,877,693 | 69,479,016 | 54,070,872 | 43,469,986 | |||||||||||||||||||||||||||||
diluted | 114,830,462 | 115,210,091 | 114,819,965 | 125,529,971 | 77,630,020 | 75,449,632 | 79,013,240 | 75,559,697 | 72,832,953 | 83,491,898 | 87,470,337 | 88,660,280 | 74,416,554 | 73,185,943 | 78,530,227 | 72,963,972 | 54,070,872 | 51,581,298 | |||||||||||||||||||||||||||||
other expense | -29,000 | -5,060,000 | -349,000 | -373,000 | -235,000 | -139,000 | -4,091,000 | -4,033,000 | -1,490,000 | ||||||||||||||||||||||||||||||||||||||
weighted-average number of shares used in computing net income (loss) per share attributable to coherus: | |||||||||||||||||||||||||||||||||||||||||||||||
basic | 114,553,537 | 115,210,091 | 114,819,965 | 112,749,306 | 77,630,020 | 75,449,632 | 79,013,240 | 75,559,697 | 72,832,953 | 71,411,705 | 71,649,350 | 71,099,773 | 70,662,185 | 69,679,916 | 69,877,693 | 69,479,016 | 54,070,872 | 43,469,986 | |||||||||||||||||||||||||||||
diluted | 114,830,462 | 115,210,091 | 114,819,965 | 125,529,971 | 77,630,020 | 75,449,632 | 79,013,240 | 75,559,697 | 72,832,953 | 83,491,898 | 87,470,337 | 88,660,280 | 74,416,554 | 73,185,943 | 78,530,227 | 72,963,972 | 54,070,872 | 51,581,298 | |||||||||||||||||||||||||||||
total revenue | 14,068,000 | 12,359,000 | 10,198,000 | 7,167,000 | 6,866,000 | 5,810,000 | 6,493,000 | 16,052,000 | |||||||||||||||||||||||||||||||||||||||
collaboration and license revenue - related party | 448,000 | 432,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||||||||||||||||||
current assets: | |||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 115,238,000 | 88,879,000 | 103,352,000 | 216,893,000 | 82,411,000 | 125,987,000 | 97,690,000 | 159,240,000 | 259,775,000 | 102,891,000 | 80,259,000 | 72,920,000 | 16,145,000 | 63,547,000 | 286,805,000 | 275,484,000 | 325,680,000 | 417,195,000 | 360,540,000 | 329,738,000 | 259,489,000 | 541,158,000 | 292,465,000 | 224,617,000 | 193,252,000 | 177,668,000 | 165,116,000 | 105,927,000 | 81,515,000 | 72,356,000 | 101,202,000 | 130,005,000 | 82,021,000 | 126,911,000 | 135,557,000 | 73,352,000 | 124,924,000 | 124,947,000 | 159,677,000 | 220,916,000 | 179,558,000 | 158,226,000 | 153,691,000 | 206,088,000 | 115,136,000 | 150,392,000 | 100,875,000 |
investments in marketable securities | 51,810,000 | 83,246,000 | 88,311,000 | 20,744,000 | 14,857,000 | 50,818,000 | 71,792,000 | 111,944,000 | 128,134,000 | 108,167,000 | 124,683,000 | 140,014,000 | 210,966,000 | 231,882,000 | 5,377,000 | 5,991,000 | 14,918,000 | 15,968,000 | 29,813,000 | 13,143,000 | 14,493,000 | 44,980,000 | 49,900,000 | ||||||||||||||||||||||||
trade receivables | 22,064,000 | 17,815,000 | 9,245,000 | 5,109,000 | 60,488,000 | 111,324,000 | 167,559,000 | 175,251,000 | 251,951,000 | 260,522,000 | 216,511,000 | 141,308,000 | 101,458,000 | 109,964,000 | 91,186,000 | 115,711,000 | 117,039,000 | 123,022,000 | 136,346,000 | 141,825,000 | 140,410,000 | 157,046,000 | 160,707,000 | 172,486,000 | 167,450,000 | 141,992,000 | 89,646,000 | 77,385,000 | 46,476,000 | ||||||||||||||||||
tsa receivables | 446,000 | 603,000 | 241,251,000 | 114,530,000 | 1,948,000 | 11,010,000 | 31,241,000 | 138,317,000 | 32,194,000 | ||||||||||||||||||||||||||||||||||||||
inventory | 4,825,000 | 3,172,000 | 2,048,000 | 4,513,000 | 3,518,000 | 70,094,000 | 47,640,000 | 62,162,000 | 61,978,000 | 62,605,000 | 66,783,000 | 63,989,000 | 49,406,000 | 38,791,000 | 27,719,000 | 31,744,000 | 36,945,000 | 37,642,000 | 37,583,000 | 39,668,000 | 51,613,000 | 44,233,000 | 35,247,000 | 27,192,000 | 16,436,000 | 9,807,000 | 7,668,000 | 4,333,000 | 2,312,000 | 1,659,000 | |||||||||||||||||
prepaid manufacturing | 2,273,000 | 6,758,000 | 8,048,000 | 6,700,000 | 6,908,000 | 11,636,000 | 10,718,000 | 9,179,000 | 7,498,000 | 23,657,000 | 13,772,000 | 17,578,000 | 16,019,000 | 17,880,000 | 20,633,000 | 7,176,000 | 13,418,000 | 13,666,000 | 20,378,000 | 15,159,000 | 15,385,000 | 19,429,000 | 21,928,000 | 14,155,000 | 11,678,000 | 8,578,000 | 5,381,000 | 6,748,000 | 8,249,000 | 7,906,000 | 9,776,000 | 10,270,000 | 14,206,000 | ||||||||||||||
other prepaids and current assets | 9,379,000 | 6,233,000 | 8,700,000 | 11,716,000 | 15,930,000 | 11,532,000 | 14,176,000 | 13,782,000 | 14,081,000 | 11,099,000 | 16,222,000 | 17,897,000 | 20,954,000 | 22,918,000 | |||||||||||||||||||||||||||||||||
total current assets | 206,035,000 | 206,706,000 | 460,955,000 | 380,205,000 | 310,175,000 | 341,583,000 | 369,024,000 | 557,931,000 | 627,477,000 | 475,631,000 | 444,365,000 | 385,484,000 | 315,926,000 | 381,234,000 | 448,275,000 | 446,784,000 | 512,443,000 | 602,323,000 | 673,039,000 | 660,013,000 | 617,261,000 | 767,479,000 | 726,920,000 | 675,860,000 | 395,183,000 | 343,009,000 | 276,375,000 | 205,630,000 | 159,158,000 | 84,433,000 | 130,314,000 | 172,781,000 | 112,241,000 | 145,477,000 | 171,605,000 | 153,342,000 | 208,260,000 | 161,486,000 | 177,319,000 | 236,834,000 | 211,583,000 | 197,386,000 | 189,302,000 | 239,592,000 | 143,897,000 | 179,136,000 | 118,875,000 |
property and equipment | 1,094,000 | 1,345,000 | 1,633,000 | 1,907,000 | 2,256,000 | 2,837,000 | 2,911,000 | 3,334,000 | 4,188,000 | 5,119,000 | 6,069,000 | 6,929,000 | 7,724,000 | 8,754,000 | 9,571,000 | 9,553,000 | 7,998,000 | 7,813,000 | 8,505,000 | 9,130,000 | 9,670,000 | 10,108,000 | 10,647,000 | 10,320,000 | 6,832,000 | 5,840,000 | 5,857,000 | 5,646,000 | 6,129,000 | 6,660,000 | 6,786,000 | 11,170,000 | 11,859,000 | 12,773,000 | 13,791,000 | 14,547,000 | 14,873,000 | 10,772,000 | 10,675,000 | 9,904,000 | 10,296,000 | 10,504,000 | 8,652,000 | 6,341,000 | 5,104,000 | 4,472,000 | 3,680,000 |
inventory, non-current | 9,688,000 | 43,776,000 | 71,375,000 | 49,879,000 | 65,645,000 | 67,495,000 | 79,002,000 | 63,846,000 | 65,081,000 | 76,260,000 | 77,438,000 | 75,954,000 | 59,427,000 | 55,610,000 | 46,357,000 | 56,413,000 | 52,065,000 | 47,956,000 | 50,717,000 | 53,792,000 | 48,632,000 | 45,264,000 | 29,941,000 | 18,465,000 | 9,700,000 | 4,012,000 | |||||||||||||||||||||
intangible assets | 45,614,000 | 46,239,000 | 49,484,000 | 52,312,000 | 52,979,000 | 53,646,000 | 54,313,000 | 55,455,000 | 57,104,000 | 71,673,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | 2,620,000 | |||||||
other assets, non-current | 3,591,000 | 4,053,000 | 4,447,000 | 5,040,000 | 5,656,000 | 6,691,000 | 7,377,000 | 8,256,000 | 9,131,000 | 9,686,000 | 7,823,000 | 7,523,000 | 7,825,000 | 8,668,000 | 9,627,000 | 10,149,000 | 9,956,000 | 10,025,000 | 10,262,000 | 10,423,000 | 10,744,000 | 2,147,000 | 976,000 | 1,637,000 | 362,000 | 362,000 | 514,000 | 14,000 | 14,000 | 14,000 | 14,000 | 14,000 | 14,000 | 13,000 | 14,000 | 14,000 | 14,000 | 1,879,000 | 15,000 | 15,000 | 9,000 | 146,000 | 10,000 | 50,000 | 589,000 | 50,000 | |
total assets | 266,022,000 | 258,343,000 | 516,519,000 | 439,464,000 | 371,066,000 | 448,533,000 | 505,000,000 | 674,855,000 | 763,545,000 | 629,604,000 | 583,783,000 | 469,591,000 | 402,426,000 | 480,847,000 | 550,907,000 | 546,003,000 | 593,387,000 | 679,334,000 | 741,726,000 | 739,542,000 | 693,303,000 | 841,649,000 | 803,733,000 | 756,611,000 | 466,539,000 | 408,927,000 | 327,383,000 | 240,456,000 | 186,115,000 | 99,467,000 | 141,462,000 | 188,313,000 | 128,462,000 | 162,611,000 | 189,758,000 | 172,251,000 | 227,495,000 | 178,485,000 | 192,357,000 | 251,101,000 | 226,236,000 | 212,384,000 | 202,312,000 | 249,546,000 | 153,153,000 | 187,221,000 | 129,182,000 |
liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 11,479,000 | 9,915,000 | 24,893,000 | 37,622,000 | 40,930,000 | 28,456,000 | 21,893,000 | 76,818,000 | 38,289,000 | 35,219,000 | 37,092,000 | 29,278,000 | 23,231,000 | 11,526,000 | 9,917,000 | 17,486,000 | 21,092,000 | 16,159,000 | 45,707,000 | 14,568,000 | 15,482,000 | 15,201,000 | 11,990,000 | 21,179,000 | 20,485,000 | 25,985,000 | 13,709,000 | 19,223,000 | 11,173,000 | 15,294,000 | 7,637,000 | 13,303,000 | 14,331,000 | 15,481,000 | 10,139,000 | 15,752,000 | 12,560,000 | 19,706,000 | 22,883,000 | 17,433,000 | 17,904,000 | 25,948,000 | 25,186,000 | 14,091,000 | 10,871,000 | 8,778,000 | 4,411,000 |
accrued rebates, fees and reserves | 28,766,000 | 30,397,000 | 67,010,000 | 96,814,000 | 147,738,000 | 164,867,000 | 163,315,000 | 177,455,000 | 155,775,000 | 169,645,000 | 117,369,000 | 84,210,000 | 55,697,000 | 54,461,000 | 54,021,000 | 64,547,000 | 71,894,000 | 79,027,000 | 84,744,000 | 83,758,000 | |||||||||||||||||||||||||||
tsa payables and accrued liabilities | 61,605,000 | 65,065,000 | 253,908,000 | 103,999,000 | |||||||||||||||||||||||||||||||||||||||||||
accrued compensation | 15,280,000 | 14,579,000 | 13,385,000 | 11,015,000 | 19,950,000 | 18,344,000 | 15,756,000 | 14,152,000 | 22,762,000 | 21,521,000 | 18,084,000 | 14,138,000 | 12,422,000 | 22,610,000 | 21,391,000 | 16,928,000 | 14,870,000 | 22,014,000 | 18,793,000 | 14,816,000 | 12,090,000 | 22,244,000 | 17,412,000 | 13,169,000 | 10,400,000 | 18,410,000 | 13,352,000 | 10,810,000 | 7,292,000 | 10,540,000 | |||||||||||||||||
accrued and other current liabilities | 15,202,000 | 20,430,000 | 13,101,000 | 14,179,000 | 46,296,000 | 60,288,000 | 60,965,000 | 61,044,000 | 115,707,000 | 105,386,000 | 67,114,000 | 41,814,000 | 32,057,000 | 50,097,000 | 85,990,000 | 41,793,000 | 45,892,000 | 48,127,000 | 45,826,000 | 54,899,000 | 44,840,000 | ||||||||||||||||||||||||||
total current liabilities | 132,332,000 | 140,386,000 | 372,297,000 | 263,629,000 | 255,042,000 | 282,981,000 | 295,566,000 | 463,005,000 | 538,303,000 | 331,771,000 | 239,659,000 | 169,440,000 | 123,407,000 | 138,694,000 | 171,319,000 | 140,754,000 | 153,748,000 | 165,327,000 | 320,348,000 | 287,052,000 | 257,601,000 | 145,653,000 | 133,432,000 | 129,763,000 | 119,011,000 | 114,969,000 | 82,701,000 | 61,226,000 | 41,407,000 | 33,261,000 | 24,537,000 | 22,198,000 | 27,624,000 | 28,395,000 | 31,430,000 | 35,947,000 | 47,296,000 | 56,376,000 | 58,386,000 | 108,284,000 | 92,920,000 | 106,018,000 | 82,519,000 | 69,947,000 | 51,913,000 | 51,783,000 | 48,077,000 |
term loan, non-current | 37,147,000 | 37,051,000 | 36,957,000 | 36,867,000 | 36,781,000 | ||||||||||||||||||||||||||||||||||||||||||
lease liabilities, non-current | 954,000 | 1,457,000 | 1,946,000 | 2,406,000 | 2,854,000 | 3,286,000 | 3,737,000 | 4,165,000 | 4,680,000 | 5,328,000 | 1,436,000 | 2,622,000 | 3,806,000 | 5,046,000 | 6,123,000 | 6,811,000 | 6,518,000 | 7,251,000 | 7,973,000 | 8,444,000 | 9,244,000 | 9,948,000 | 10,729,000 | 11,304,000 | 11,138,000 | 10,256,000 | 10,827,000 | 5,977,000 | 6,549,000 | ||||||||||||||||||
other liabilities, non-current | 16,966,000 | 18,435,000 | 17,545,000 | 16,735,000 | 31,290,000 | 29,329,000 | 29,161,000 | 27,697,000 | 2,734,000 | 12,561,000 | 3,513,000 | 102,000 | 102,000 | 3,467,000 | 102,000 | 102,000 | 102,000 | 750,000 | 750,000 | 751,000 | 750,000 | 949,000 | 705,000 | 1,645,000 | 1,753,000 | 1,856,000 | 1,960,000 | 2,073,000 | 2,163,000 | 2,111,000 | 1,932,000 | 1,830,000 | 1,716,000 | 1,591,000 | 1,643,000 | 1,702,000 | 1,746,000 | 319,000 | 334,000 | 347,000 | 130,000 | ||||||
total liabilities | 187,399,000 | 197,329,000 | 428,745,000 | 319,637,000 | 554,536,000 | 580,523,000 | 592,973,000 | 758,963,000 | 845,389,000 | 823,029,000 | 717,382,000 | 644,355,000 | 598,933,000 | 618,265,000 | 648,040,000 | 568,632,000 | 580,824,000 | 581,608,000 | 610,966,000 | 583,322,000 | 565,632,000 | 560,675,000 | 548,002,000 | 543,234,000 | 309,264,000 | 303,713,000 | 271,360,000 | 244,441,000 | 224,630,000 | 138,058,000 | 129,068,000 | 126,482,000 | 131,550,000 | 132,076,000 | 134,851,000 | 141,394,000 | 150,536,000 | 159,131,000 | 160,635,000 | 313,049,000 | 293,114,000 | 219,313,000 | 162,272,000 | 153,182,000 | 115,160,000 | 120,464,000 | 120,003,000 |
commitments and contingencies | |||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ equity: | |||||||||||||||||||||||||||||||||||||||||||||||
preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||
common stock | 15,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 11,000 | 11,000 | 11,000 | 9,000 | 8,000 | 8,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | ||||||||||
additional paid-in capital | 1,500,172,000 | 1,444,166,000 | 1,433,291,000 | 1,429,885,000 | 1,424,355,000 | 1,419,266,000 | 1,412,587,000 | 1,405,698,000 | 1,395,042,000 | 1,386,312,000 | 1,366,502,000 | 1,285,730,000 | 1,221,100,000 | 1,204,431,000 | 1,185,868,000 | 1,173,722,000 | 1,158,766,000 | 1,147,843,000 | 1,135,155,000 | 1,122,081,000 | 1,063,672,000 | 1,043,991,000 | 1,028,441,000 | 1,014,022,000 | 1,016,644,000 | 1,000,763,000 | 990,693,000 | 977,787,000 | 966,731,000 | 946,515,000 | 935,042,000 | 927,129,000 | 818,753,000 | 808,060,000 | 783,359,000 | 700,244,000 | 691,078,000 | 558,474,000 | 494,831,000 | 484,967,000 | 409,812,000 | 404,175,000 | 398,636,000 | 383,522,000 | 266,246,000 | 254,048,000 | 5,888,000 |
accumulated other comprehensive loss | -268,000 | -195,000 | -203,000 | -275,000 | -275,000 | -275,000 | -275,000 | -272,000 | -272,000 | -248,000 | -265,000 | -297,000 | -278,000 | -249,000 | -270,000 | -270,000 | -272,000 | -270,000 | -273,000 | -267,000 | -307,000 | -270,000 | -255,000 | -257,000 | 50,000 | -558,000 | -452,000 | -511,000 | -418,000 | -282,000 | -420,000 | -537,000 | -764,000 | -750,000 | -745,000 | -673,000 | -807,000 | -630,000 | -562,000 | -524,000 | -449,000 | -401,000 | -473,000 | -520,000 | -648,000 | -525,000 | -128,000 |
accumulated deficit | -1,421,296,000 | -1,382,969,000 | -1,345,326,000 | -1,309,795,000 | -1,607,562,000 | -1,550,993,000 | -1,500,297,000 | -1,489,546,000 | -1,476,625,000 | -1,579,500,000 | -1,499,847,000 | -1,460,206,000 | -1,417,337,000 | -1,341,608,000 | -1,282,738,000 | -1,196,088,000 | -1,145,938,000 | -1,049,854,000 | -1,004,129,000 | -965,601,000 | -935,701,000 | -762,754,000 | -772,462,000 | -800,395,000 | -859,426,000 | -894,998,000 | -934,225,000 | -981,268,000 | -1,004,835,000 | -984,831,000 | -922,235,000 | -863,427,000 | -819,789,000 | -775,492,000 | -726,425,000 | -667,436,000 | -612,100,000 | -537,322,000 | -461,401,000 | -545,340,000 | -475,373,000 | -409,985,000 | -357,594,000 | -286,260,000 | -227,450,000 | -186,725,000 | -157,591,000 |
total stockholders' equity | 78,623,000 | 61,014,000 | 87,774,000 | 119,827,000 | -137,418,000 | -97,133,000 | -22,629,000 | 12,563,000 | 97,726,000 | 130,760,000 | 156,220,000 | 127,671,000 | 280,974,000 | 255,731,000 | 213,377,000 | 157,275,000 | 105,214,000 | 56,023,000 | -38,591,000 | 12,394,000 | 61,831,000 | -3,088,000 | 30,535,000 | 54,907,000 | 30,857,000 | 76,959,000 | 19,354,000 | 31,722,000 | -6,929,000 | 40,040,000 | 96,364,000 | 37,993,000 | 66,757,000 | ||||||||||||||
total liabilities and stockholders’ equity | 266,022,000 | 258,343,000 | 516,519,000 | 439,464,000 | 480,847,000 | 550,907,000 | 546,003,000 | 593,387,000 | 679,334,000 | 741,726,000 | 739,542,000 | 693,303,000 | 841,649,000 | 803,733,000 | 756,611,000 | 466,539,000 | 408,927,000 | 327,383,000 | 99,467,000 | 141,462,000 | 188,313,000 | 128,462,000 | 162,611,000 | 189,758,000 | 172,251,000 | 227,495,000 | 178,485,000 | 192,357,000 | 212,384,000 | 202,312,000 | 249,546,000 | 153,153,000 | |||||||||||||||
assets of discontinued operations, current | |||||||||||||||||||||||||||||||||||||||||||||||
assets of discontinued operations, non-current | |||||||||||||||||||||||||||||||||||||||||||||||
convertible notes, non-current | |||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ equity | |||||||||||||||||||||||||||||||||||||||||||||||
assets held for sale, current | 138,972,000 | ||||||||||||||||||||||||||||||||||||||||||||||
assets held for sale, non-current | |||||||||||||||||||||||||||||||||||||||||||||||
liabilities and stockholders’ deficit | |||||||||||||||||||||||||||||||||||||||||||||||
tsa payables and other accrued liabilities | 128,000 | 11,026,000 | 33,637,000 | 133,536,000 | 30,770,000 | ||||||||||||||||||||||||||||||||||||||||||
convertible notes | 228,569,000 | 228,229,000 | 227,891,000 | 227,555,000 | 227,220,000 | 226,888,000 | 226,557,000 | 226,228,000 | 225,900,000 | 225,575,000 | 225,250,000 | 224,928,000 | 224,607,000 | 78,866,000 | 78,542,000 | 78,226,000 | 77,916,000 | 77,614,000 | 77,319,000 | 77,031,000 | 76,750,000 | 76,474,000 | 76,206,000 | 75,944,000 | 75,687,000 | 75,437,000 | 75,192,000 | 74,953,000 | 74,720,000 | 74,492,000 | |||||||||||||||||
stockholders’ deficit: | |||||||||||||||||||||||||||||||||||||||||||||||
total stockholders' deficit | -183,470,000 | -131,990,000 | -87,973,000 | -84,108,000 | -81,844,000 | -193,425,000 | -133,599,000 | -174,764,000 | -196,507,000 | -3,985,000 | -38,515,000 | -61,948,000 | -66,878,000 | -151,985,000 | |||||||||||||||||||||||||||||||||
total liabilities and stockholders’ deficit | 371,066,000 | 448,533,000 | 505,000,000 | 674,855,000 | 763,545,000 | 629,604,000 | 583,783,000 | 469,591,000 | 402,426,000 | 240,456,000 | 186,115,000 | 251,101,000 | 226,236,000 | ||||||||||||||||||||||||||||||||||
term loans, non-current | 36,698,000 | 36,618,000 | 36,541,000 | 72,452,000 | |||||||||||||||||||||||||||||||||||||||||||
term loans, current | 175,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
term loans | 246,481,000 | 246,217,000 | 245,963,000 | 245,718,000 | 245,483,000 | 245,246,000 | 196,037,000 | 195,849,000 | |||||||||||||||||||||||||||||||||||||||
goodwill and intangible assets | 46,524,000 | 5,809,000 | 5,870,000 | 5,931,000 | 5,996,000 | 3,563,000 | 3,563,000 | ||||||||||||||||||||||||||||||||||||||||
other prepaid and other assets | 21,932,000 | 16,669,000 | 19,361,000 | 10,798,000 | 10,025,000 | 8,940,000 | 10,350,000 | 5,613,000 | 5,607,000 | 5,528,000 | 6,367,000 | 4,964,000 | 3,137,000 | 5,196,000 | 5,638,000 | ||||||||||||||||||||||||||||||||
goodwill | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | 943,000 | |||||||||||||||||
2022 convertible notes | 81,359,000 | ||||||||||||||||||||||||||||||||||||||||||||||
2022 convertible notes - related parties | 27,120,000 | ||||||||||||||||||||||||||||||||||||||||||||||
2026 convertible notes | 224,288,000 | ||||||||||||||||||||||||||||||||||||||||||||||
2025 term loan | 75,513,000 | ||||||||||||||||||||||||||||||||||||||||||||||
convertible notes due 2022 - current | 80,978,000 | 80,605,000 | 80,240,000 | ||||||||||||||||||||||||||||||||||||||||||||
convertible notes due 2022 - related parties, current | 26,992,000 | 26,868,000 | 26,747,000 | ||||||||||||||||||||||||||||||||||||||||||||
term loan - current portion | 17,308,000 | 11,538,000 | |||||||||||||||||||||||||||||||||||||||||||||
convertible notes due 2022 | 79,885,000 | 79,537,000 | 79,198,000 | ||||||||||||||||||||||||||||||||||||||||||||
convertible notes due 2022 - related parties | 26,628,000 | 26,512,000 | 26,399,000 | ||||||||||||||||||||||||||||||||||||||||||||
convertible notes due 2026 | 223,971,000 | 223,655,000 | 223,341,000 | 223,029,000 | 222,718,000 | 222,409,000 | |||||||||||||||||||||||||||||||||||||||||
term loan - non-current portion | 57,924,000 | 63,420,000 | |||||||||||||||||||||||||||||||||||||||||||||
accrued rebates, fees and reserve | 78,202,000 | 81,529,000 | 75,961,000 | 66,229,000 | 66,157,000 | 51,120,000 | 37,121,000 | 20,650,000 | 11,945,000 | ||||||||||||||||||||||||||||||||||||||
term loan | 74,696,000 | 74,481,000 | 74,267,000 | 74,059,000 | 73,858,000 | 73,663,000 | 73,472,000 | 73,286,000 | 73,124,000 | ||||||||||||||||||||||||||||||||||||||
operating lease right-of-use assets | 9,956,000 | 10,470,000 | 10,999,000 | 11,527,000 | 10,649,000 | 11,133,000 | 6,353,000 | 6,766,000 | |||||||||||||||||||||||||||||||||||||||
restricted cash, non-current | 440,000 | 440,000 | 440,000 | 440,000 | 240,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | ||||||||||||||||||||||||||
accrued liabilities | 22,818,000 | 23,446,000 | 25,560,000 | 19,520,000 | 17,258,000 | 16,474,000 | 8,295,000 | 8,857,000 | 7,008,000 | 16,498,000 | 8,510,000 | 9,394,000 | 9,050,000 | 18,204,000 | 18,429,000 | 24,667,000 | 28,022,000 | 24,875,000 | 19,184,000 | 19,279,000 | 24,133,000 | 25,170,000 | 19,280,000 | 13,271,000 | 11,231,000 | ||||||||||||||||||||||
other current liabilities | 3,861,000 | 4,623,000 | 3,626,000 | 2,449,000 | 2,196,000 | 419,000 | |||||||||||||||||||||||||||||||||||||||||
contingent consideration, non-current | 102,000 | 102,000 | 102,000 | 102,000 | 102,000 | 59,000 | 64,000 | 64,000 | 60,000 | 70,000 | 95,000 | 2,420,000 | 1,060,000 | 925,000 | 860,000 | 785,000 | 620,000 | ||||||||||||||||||||||||||||||
convertible notes - related parties | 26,289,000 | 26,181,000 | 26,075,000 | 25,972,000 | 25,872,000 | 25,773,000 | 25,677,000 | 25,583,000 | 25,492,000 | 25,402,000 | 25,314,000 | 25,229,000 | 25,146,000 | 25,064,000 | 24,985,000 | 24,907,000 | 24,831,000 | ||||||||||||||||||||||||||||||
restricted cash | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 50,000 | ||||||||||||||||||||||||||
common stock, 0.0001 par value... | 7,000 | 7,000 | 6,000 | 5,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 1,000 | |||||||||||||||||||||||||||||||||||||
other liabilities | 2,045,000 | 2,198,000 | 2,140,000 | 402,000 | 385,000 | 367,000 | 341,000 | 322,000 | 308,000 | 281,000 | 259,000 | 251,000 | 209,000 | 205,000 | 193,000 | 223,000 | 62,000 | 56,000 | 52,000 | ||||||||||||||||||||||||||||
accounts payable - related parties | 50,000 | 34,000 | 233,000 | 5,000 | 388,000 | 2,109,000 | 877,000 | 2,860,000 | 2,430,000 | 3,494,000 | 3,548,000 | 3,092,000 | 5,509,000 | 3,723,000 | 2,020,000 | 4,963,000 | |||||||||||||||||||||||||||||||
other prepaid assets | 2,379,000 | 3,139,000 | 2,498,000 | 2,789,000 | |||||||||||||||||||||||||||||||||||||||||||
other assets | 83,000 | 179,000 | 145,000 | 32,000 | 142,000 | 392,000 | 735,000 | 2,866,000 | 2,986,000 | 518,000 | 431,000 | 4,785,000 | 2,797,000 | 3,333,000 | 3,344,000 | 3,044,000 | 2,276,000 | 3,064,000 | |||||||||||||||||||||||||||||
contingent consideration, current | |||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 0.0001 par value... | |||||||||||||||||||||||||||||||||||||||||||||||
total coherus stockholders' equity | -38,591,000 | 12,394,000 | 63,172,000 | -1,794,000 | 31,824,000 | 56,195,000 | 32,140,000 | 78,176,000 | 20,527,000 | 32,872,000 | -6,207,000 | 40,573,000 | 96,746,000 | 38,151,000 | 66,801,000 | ||||||||||||||||||||||||||||||||
non-controlling interest | -1,341,000 | -1,294,000 | -1,289,000 | -1,288,000 | -1,283,000 | -1,217,000 | -1,173,000 | -1,150,000 | -1,055,000 | -872,000 | -722,000 | -533,000 | -382,000 | -158,000 | -44,000 | -155,000 | |||||||||||||||||||||||||||||||
contingent consideration | 3,498,000 | 3,290,000 | 2,760,000 | 5,940,000 | 5,550,000 | 4,990,000 | 6,570,000 | 1,435,000 | 1,245,000 | 5,710,000 | 3,430,000 | ||||||||||||||||||||||||||||||||||||
receivables from collaboration and license agreement | 26,000 | 1,859,000 | 419,000 | 419,000 | 1,195,000 | 1,560,000 | 540,000 | 1,454,000 | 2,015,000 | 2,417,000 | |||||||||||||||||||||||||||||||||||||
prepaid assets | 18,364,000 | 21,103,000 | 34,215,000 | 30,484,000 | 31,634,000 | 16,645,000 | 15,008,000 | 25,985,000 | 34,743,000 | 31,678,000 | 26,955,000 | 20,114,000 | 20,485,000 | 17,950,000 | |||||||||||||||||||||||||||||||||
advance payments under license agreement | 1,070,000 | 1,070,000 | 1,070,000 | 1,150,000 | 1,200,000 | 970,000 | 1,330,000 | 1,192,000 | 1,192,000 | ||||||||||||||||||||||||||||||||||||||
deferred revenue | 669,000 | 892,000 | 1,377,000 | 61,258,000 | 49,633,000 | 49,621,000 | 28,848,000 | 31,005,000 | 22,800,000 | 22,800,000 | 25,176,000 | ||||||||||||||||||||||||||||||||||||
deferred revenue, non-current | 725,000 | 669,000 | 595,000 | 26,792,000 | 32,973,000 | 45,338,000 | 33,447,000 | 38,491,000 | 34,403,000 | 39,899,000 | 43,526,000 | ||||||||||||||||||||||||||||||||||||
contingent liability to collaborator | 76,755,000 | 66,255,000 | 66,255,000 | 43,500,000 | 43,500,000 | 27,650,000 | 27,650,000 | 27,650,000 | |||||||||||||||||||||||||||||||||||||||
total coherus stockholders' deficit | -60,893,000 | -66,006,000 | -151,830,000 | ||||||||||||||||||||||||||||||||||||||||||||
notes receivable | 1,837,000 | 1,815,000 | |||||||||||||||||||||||||||||||||||||||||||||
other assets - related party | 1,691,000 | 1,691,000 | 1,691,000 | ||||||||||||||||||||||||||||||||||||||||||||
notes receivable from related parties | |||||||||||||||||||||||||||||||||||||||||||||||
liabilities, convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||||||||||
convertible preferred stock warrant liability | 2,296,000 | ||||||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock, 0.0001 par value... | 1,191,000 | ||||||||||||||||||||||||||||||||||||||||||||||
series b convertible preferred stock, 0.0001 par value... | 94,630,000 | ||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, convertible preferred stock and stockholders’ equity | 187,221,000 | ||||||||||||||||||||||||||||||||||||||||||||||
receivables from related parties | |||||||||||||||||||||||||||||||||||||||||||||||
liabilities, convertible preferred stock and stockholders’ deficit | |||||||||||||||||||||||||||||||||||||||||||||||
accrued and other liabilities | 7,801,000 | ||||||||||||||||||||||||||||||||||||||||||||||
series c convertible preferred stock, 0.0001 par value... | 65,343,000 | ||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, convertible preferred stock and stockholders’ deficit | 129,182,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating activities | ||||||||||||||||||||||||||||||||||||||||||||||
net loss | -38,327,000 | -79,653,000 | -39,641,000 | -42,869,000 | -75,729,000 | -86,650,000 | -50,150,000 | -96,084,000 | -20,004,000 | -62,596,000 | -58,826,000 | -43,685,000 | -44,302,000 | -49,069,000 | -58,993,000 | -55,402,000 | -74,822,000 | -75,944,000 | 83,844,000 | -70,150,000 | -65,538,000 | -52,580,000 | -71,485,000 | -59,034,000 | -40,839,000 | -29,023,000 | ||||||||||||||||||||
adjustments to reconcile net loss to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 881,000 | 896,000 | 966,000 | 1,016,000 | 1,046,000 | 1,033,000 | 1,549,000 | 1,187,000 | 1,507,000 | 1,063,000 | 899,000 | 880,000 | 949,000 | 1,050,000 | 995,000 | 887,000 | 767,000 | 836,000 | 892,000 | 877,000 | 849,000 | 840,000 | 693,000 | 748,000 | 607,000 | 1,055,000 | 839,000 | 674,000 | 691,000 | 613,000 | 798,000 | 902,000 | 922,000 | 926,000 | 770,000 | 837,000 | 865,000 | 797,000 | 753,000 | 729,000 | 717,000 | 601,000 | 636,000 | 400,000 | 232,000 | 235,000 |
stock-based compensation expense | 2,385,000 | 2,784,000 | 3,389,000 | 5,421,000 | 5,372,000 | 6,384,000 | 6,868,000 | 7,231,000 | 7,319,000 | 10,798,000 | 9,953,000 | 10,077,000 | 12,282,000 | 11,726,000 | 12,282,000 | 13,850,000 | 12,879,000 | 10,946,000 | 11,939,000 | 11,595,000 | 16,884,000 | 9,873,000 | 9,307,000 | 9,425,000 | 9,555,000 | 7,272,000 | 8,833,000 | 7,992,000 | 9,494,000 | 8,827,000 | 8,560,000 | 8,690,000 | 8,720,000 | 8,332,000 | 8,183,000 | 9,072,000 | 7,810,000 | 7,685,000 | 8,270,000 | 6,148,000 | 5,318,000 | 5,174,000 | 4,744,000 | 4,621,000 | 2,182,000 | 3,826,000 |
loss on sale transactions | 388,000 | |||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivatives | 0 | 0 | 0 | 12,608,000 | ||||||||||||||||||||||||||||||||||||||||||
other non-cash adjustments | 468,000 | -4,976,000 | -7,842,000 | 1,632,000 | 858,000 | -4,966,000 | 762,000 | 1,428,000 | -2,695,000 | -578,000 | -86,000 | -1,383,000 | 554,000 | -46,000 | 636,000 | 616,000 | 592,000 | 407,000 | 0 | 8,000 | 173,000 | 4,000 | 96,000 | -310,000 | 636,000 | |||||||||||||||||||||
changes in operating assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||
trade receivables | -4,282,000 | -8,338,000 | -4,266,000 | 55,270,000 | 50,891,000 | 56,326,000 | 7,807,000 | 76,638,000 | 8,579,000 | -44,057,000 | -75,276,000 | -39,879,000 | 8,529,000 | -18,797,000 | 24,522,000 | 1,336,000 | 5,991,000 | 13,340,000 | 5,479,000 | -1,420,000 | 16,663,000 | 3,667,000 | 11,792,000 | -5,051,000 | -25,626,000 | -52,346,000 | -12,261,000 | -30,909,000 | -46,476,000 | |||||||||||||||||
inventory | -11,312,000 | -1,114,000 | 2,480,000 | 3,770,000 | -22,244,000 | -6,453,000 | -6,942,000 | -7,102,000 | -11,455,000 | -11,793,000 | -19,226,000 | -13,044,000 | -2,671,000 | -9,792,000 | -23,353,000 | -11,241,000 | -2,962,000 | -9,189,000 | 6,796,000 | 7,518,000 | -11,378,000 | -6,135,000 | -4,817,000 | -15,628,000 | -9,608,000 | -17,033,000 | -14,445,000 | -10,274,000 | -6,432,000 | |||||||||||||||||
prepaid manufacturing | 4,485,000 | 1,290,000 | -1,348,000 | 208,000 | 188,000 | -918,000 | -1,588,000 | -2,419,000 | 9,589,000 | -2,081,000 | 3,806,000 | -1,559,000 | 1,861,000 | 2,753,000 | -13,457,000 | 6,242,000 | 248,000 | 6,712,000 | -5,219,000 | 226,000 | 2,109,000 | 2,499,000 | -7,773,000 | -2,477,000 | -3,100,000 | -3,197,000 | 1,367,000 | 1,501,000 | -343,000 | 1,870,000 | 494,000 | 3,936,000 | 763,000 | |||||||||||||
other prepaid, current and non-current assets | -3,071,000 | 2,367,000 | 3,274,000 | 4,465,000 | -5,334,000 | 3,468,000 | -57,000 | 177,000 | -4,426,000 | 5,453,000 | 5,917,000 | 2,728,000 | 2,057,000 | -915,000 | -6,286,000 | 1,409,000 | -7,632,000 | -761,000 | -1,034,000 | 1,065,000 | -4,621,000 | |||||||||||||||||||||||||
accounts payable | 2,564,000 | -5,088,000 | -15,301,000 | -12,209,000 | 13,042,000 | 6,342,000 | -50,357,000 | 39,461,000 | 616,000 | -785,000 | 6,759,000 | 6,047,000 | 11,739,000 | 1,601,000 | -7,572,000 | -3,334,000 | 4,757,000 | -29,621,000 | 31,268,000 | -976,000 | 203,000 | 3,288,000 | -7,976,000 | -173,000 | -4,959,000 | 11,329,000 | -5,460,000 | 7,988,000 | -3,964,000 | 7,456,000 | -5,424,000 | -1,265,000 | -1,068,000 | 5,388,000 | -5,372,000 | 3,439,000 | -7,265,000 | -3,323,000 | 5,728,000 | -573,000 | -6,797,000 | -696,000 | 12,021,000 | 4,052,000 | 3,027,000 | 3,077,000 |
accrued rebates, fees and reserves | -1,631,000 | -30,213,000 | -21,061,000 | -50,924,000 | -17,129,000 | 1,552,000 | -14,140,000 | 21,680,000 | -15,157,000 | 52,503,000 | 34,219,000 | 25,147,000 | 1,236,000 | 440,000 | -10,526,000 | -7,347,000 | -7,133,000 | -5,717,000 | 986,000 | |||||||||||||||||||||||||||
tsa related operating assets and liabilities | -3,303,000 | 51,805,000 | 23,188,000 | 7,177,000 | -3,357,000 | -1,424,000 | ||||||||||||||||||||||||||||||||||||||||
accrued compensation | 33,000 | 1,194,000 | 2,370,000 | -8,935,000 | 1,606,000 | 2,588,000 | 1,604,000 | -4,202,000 | 1,559,000 | 3,437,000 | -338,000 | 1,716,000 | -10,188,000 | 1,219,000 | 4,463,000 | 2,058,000 | -7,144,000 | 3,221,000 | 3,977,000 | 2,726,000 | -10,154,000 | 4,832,000 | 4,243,000 | 2,769,000 | -5,632,000 | 5,873,000 | 2,542,000 | 3,518,000 | -1,898,000 | |||||||||||||||||
accrued and other current and non-current liabilities | -7,164,000 | 4,437,000 | 1,275,000 | -6,586,000 | -8,325,000 | -5,971,000 | -5,034,000 | -46,612,000 | 741,000 | 3,692,000 | 16,519,000 | 12,615,000 | -21,909,000 | -31,122,000 | 40,903,000 | -5,344,000 | -3,242,000 | 1,406,000 | -9,935,000 | 9,564,000 | 16,897,000 | |||||||||||||||||||||||||
net cash from operating activities | -57,886,000 | -19,716,000 | -46,339,000 | -46,632,000 | -25,826,000 | 28,608,000 | -62,016,000 | 59,734,000 | -46,766,000 | -12,937,000 | -54,300,000 | -38,915,000 | -68,732,000 | -99,953,000 | -37,089,000 | -50,037,000 | -54,045,000 | -52,322,000 | 13,711,000 | -188,000 | 1,367,000 | 33,124,000 | 47,353,000 | 60,191,000 | 13,477,000 | 17,710,000 | 54,951,000 | 12,677,000 | -56,983,000 | -47,363,000 | -42,789,000 | -35,530,000 | -33,584,000 | -29,922,000 | -41,513,000 | -55,574,000 | -73,277,000 | -86,892,000 | -61,948,000 | -27,389,000 | -76,316,000 | 5,567,000 | -59,655,000 | -20,840,000 | -33,062,000 | -33,285,000 |
capital expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -34,000 | 0 | -100,000 | -152,000 | -87,000 | -457,000 | -880,000 | -615,000 | -468,000 | -261,000 | -415,000 | -145,000 | -952,000 | -2,112,000 | -2,384,000 | -1,783,000 | -387,000 | -918,000 | -182,000 | -335,000 | -214,000 | -489,000 | -5,000 | -81,000 | -109,000 | -1,812,000 | -961,000 | -1,691,000 | -3,566,000 | -500,000 | -301,000 | -2,148,000 | -1,444,000 | -2,399,000 | -1,008,000 | -1,313,000 | -489,000 |
free cash flows | -57,886,000 | -19,716,000 | -46,339,000 | -46,632,000 | -25,826,000 | 28,608,000 | -62,016,000 | 59,734,000 | -46,766,000 | -12,971,000 | -54,300,000 | -39,015,000 | -68,884,000 | -100,040,000 | -37,546,000 | -50,917,000 | -54,660,000 | -52,790,000 | 13,450,000 | -603,000 | 1,222,000 | 32,172,000 | 45,241,000 | 57,807,000 | 11,694,000 | 17,323,000 | 54,033,000 | 12,495,000 | -57,318,000 | -47,577,000 | -43,278,000 | -35,535,000 | -33,665,000 | -30,031,000 | -43,325,000 | -56,535,000 | -74,968,000 | -90,458,000 | -62,448,000 | -27,690,000 | -78,464,000 | 4,123,000 | -62,054,000 | -21,848,000 | -34,375,000 | -33,774,000 |
investing activities | ||||||||||||||||||||||||||||||||||||||||||||||
purchases of investments in marketable securities | -6,388,000 | -14,262,000 | -68,850,000 | 0 | 0 | -10,706,000 | -31,449,000 | 0 | -140,330,000 | 0 | -41,981,000 | 0 | -5,371,000 | 0 | -14,864,000 | 0 | 0 | -29,769,000 | -13,100,000 | |||||||||||||||||||||||||||
proceeds from maturities of investments in marketable securities | 38,135,000 | 19,812,000 | 0 | 0 | 0 | 6,200,000 | 36,212,000 | 43,398,000 | 47,250,000 | 17,500,000 | 36,992,000 | 47,700,000 | 211,000,000 | 5,400,000 | 6,000,000 | |||||||||||||||||||||||||||||||
cash paid related to the sale transactions | ||||||||||||||||||||||||||||||||||||||||||||||
milestone payment to junshi biosciences | 0 | 0 | -12,500,000 | |||||||||||||||||||||||||||||||||||||||||||
other investing activities | -1,092,000 | -12,000 | -27,000 | -36,000 | -267,000 | -542,000 | 444,000 | 156,000 | 52,000 | |||||||||||||||||||||||||||||||||||||
net cash from investing activities | 30,655,000 | -2,838,000 | -67,227,000 | 462,638,000 | -17,486,000 | -542,000 | 444,000 | 27,656,000 | 202,763,000 | 35,203,000 | 50,546,000 | 41,365,000 | 17,526,000 | -129,898,000 | -457,000 | -880,000 | -35,615,000 | 107,490,000 | 15,990,000 | 23,585,000 | -285,475,000 | 210,056,000 | 16,407,000 | -239,248,000 | -1,616,000 | -6,062,000 | -289,000 | 8,818,000 | -15,199,000 | 15,786,000 | 12,811,000 | -16,604,000 | -13,181,000 | 14,391,000 | 28,706,000 | 4,064,000 | -51,578,000 | -3,566,000 | -500,000 | -301,000 | -2,148,000 | -1,444,000 | -3,184,000 | -1,008,000 | -1,313,000 | -499,000 |
financing activities | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock under public offering, net of issuance costs | 53,650,000 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||
taxes paid related to net share settlement | -112,000 | 0 | -3,000 | -16,000 | -264,000 | -10,000 | -10,000 | -1,711,000 | -745,000 | -326,000 | ||||||||||||||||||||||||||||||||||||
other financing activities | 52,000 | 22,000 | 5,000 | 0 | -7,000 | -75,000 | -166,000 | -199,000 | -210,000 | -272,000 | -353,000 | -367,000 | -380,000 | -300,000 | -181,000 | -147,000 | ||||||||||||||||||||||||||||||
net cash from financing activities | 53,590,000 | 8,081,000 | 2,000 | -281,524,000 | -264,000 | 231,000 | -167,000 | -187,925,000 | 887,000 | 366,000 | 11,105,000 | 54,325,000 | 3,804,000 | 6,593,000 | 48,867,000 | 721,000 | -1,855,000 | 1,487,000 | 1,101,000 | 46,852,000 | 2,439,000 | 5,513,000 | 4,088,000 | 210,422,000 | 3,923,000 | 1,200,000 | 3,683,000 | 3,010,000 | 81,477,000 | 2,593,000 | 1,058,000 | 99,892,000 | 1,878,000 | 6,892,000 | 75,082,000 | -184,000 | 124,997,000 | 55,999,000 | 1,254,000 | 69,083,000 | 99,843,000 | 330,000 | 10,463,000 | 112,625,000 | -729,000 | 83,766,000 |
net increase in cash, cash equivalents and restricted cash | 26,359,000 | 134,482,000 | -43,576,000 | 28,297,000 | -61,739,000 | -100,535,000 | 156,884,000 | 22,632,000 | 7,351,000 | 56,655,000 | 30,802,000 | 70,249,000 | -281,669,000 | 248,693,000 | 67,848,000 | 31,365,000 | 15,784,000 | 12,742,000 | 58,404,000 | 24,412,000 | 9,159,000 | |||||||||||||||||||||||||
cash, cash equivalents and restricted cash at beginning of period | 89,119,000 | 0 | 0 | 0 | 126,250,000 | 0 | 0 | 0 | 103,343,000 | 0 | 0 | 0 | 63,987,000 | 0 | 0 | 0 | 417,635,000 | 0 | 0 | 0 | 541,598,000 | 0 | 0 | 0 | 177,908,000 | 0 | 0 | |||||||||||||||||||
cash, cash equivalents and restricted cash at end of period | 115,478,000 | -14,473,000 | -113,564,000 | 134,482,000 | 82,674,000 | 28,297,000 | -61,739,000 | -100,535,000 | 260,227,000 | 22,632,000 | 7,351,000 | 56,775,000 | 16,585,000 | -223,258,000 | 11,321,000 | -50,196,000 | 326,120,000 | 56,655,000 | 30,802,000 | 70,249,000 | 259,929,000 | 248,693,000 | 67,848,000 | 31,365,000 | 193,692,000 | 12,742,000 | 58,404,000 | |||||||||||||||||||
net income | -37,643,000 | -35,531,000 | 297,767,000 | -56,569,000 | -50,696,000 | -10,751,000 | -12,921,000 | 102,875,000 | -45,725,000 | -38,528,000 | -29,900,000 | -172,947,000 | 9,708,000 | 27,933,000 | 59,031,000 | 35,572,000 | 39,227,000 | 47,043,000 | ||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||
write-down of intangible assets and remeasurement of contingent consideration liabilities | ||||||||||||||||||||||||||||||||||||||||||||||
loss on debt extinguishment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6,222,000 | ||||||||||||||||||||||||||||||||||||||
gain on sale transactions | 365,000 | 422,000 | 57,000 | 1,086,000 | ||||||||||||||||||||||||||||||||||||||||||
inventory write-downs | 11,662,000 | 0 | 0 | 2,481,000 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of investments in marketable securities | 0 | 0 | 0 | 8,688,000 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||
net cash received related to the sale transactions | -8,376,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
milestone payments to junshi biosciences | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from 2029 term loan, net of debt discount and issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from (repayment of) revenue purchase and sale agreement, net of issuance costs | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock under private placement, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock under sales agreement, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from purchase under the employee stock purchase plan | 165,000 | 0 | 241,000 | 0 | 472,000 | 0 | 665,000 | 0 | 1,017,000 | 0 | 1,244,000 | 0 | ||||||||||||||||||||||||||||||||||
redemption of 2026 convertible notes, including transaction costs | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
repayment of 2027 term loans, premiums and make-whole | ||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of cash flow information | ||||||||||||||||||||||||||||||||||||||||||||||
cash paid for interest | ||||||||||||||||||||||||||||||||||||||||||||||
income taxes paid (refunded) | ||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of non-cash activities | ||||||||||||||||||||||||||||||||||||||||||||||
non-cash employee bonuses settled in common stock | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
impairment of out-license asset and remeasurement of cvr liability | 0 | 0 | 0 | 6,772,000 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock under atm offering, net of issuance costs | 0 | 0 | -52,000 | 1,507,000 | -105,000 | 11,437,000 | -74,000 | 6,835,000 | ||||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | -47,402,000 | 11,321,000 | -50,196,000 | -91,515,000 | -44,900,000 | |||||||||||||||||||||||||||||||||||||||||
financing issuance costs in accrued and other current liabilities | ||||||||||||||||||||||||||||||||||||||||||||||
tsa related operating assets and liabilities net | -1,836,000 | |||||||||||||||||||||||||||||||||||||||||||||
cash received related to the sale transactions | -4,719,000 | |||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense from amortization of debt and other financial liabilities discount and issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
non-cash operating lease expense | 460,000 | 738,000 | 589,000 | 552,000 | 540,000 | 526,000 | 514,000 | 529,000 | 528,000 | 510,000 | 484,000 | 487,000 | 413,000 | 405,000 | ||||||||||||||||||||||||||||||||
option payment to junshi biosciences | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
cash received from cimerli sale | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
cash received from yusimry sale | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents acquired as part of the surface acquisition | ||||||||||||||||||||||||||||||||||||||||||||||
milestone and option payments to junshi biosciences | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from revenue purchase and sale agreement, net of issuance costs | 0 | -9,000 | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock upon exercise of stock options | 0 | 0 | 0 | 291,000 | 524,000 | 53,000 | 14,000 | 103,000 | 60,000 | 79,000 | 8,000 | 544,000 | 673,000 | 1,280,000 | 4,117,000 | 4,329,000 | 4,414,000 | 4,909,000 | 3,302,000 | 4,803,000 | 3,789,000 | 947,000 | 448,000 | 1,269,000 | 284,000 | 225,000 | 99,000 | 80,000 | 265,000 | 1,593,000 | 66,000 | 298,000 | 468,000 | |||||||||||||
proceeds from 2027 term loans, net of debt discount and issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
repayment of 2022 convertible notes and premiums | 0 | 0 | 0 | -109,000,000 | ||||||||||||||||||||||||||||||||||||||||||
repayment of 2025 term loan, premiums and exit fees | 0 | 0 | 0 | -81,750,000 | ||||||||||||||||||||||||||||||||||||||||||
capitalized and accrued milestone payment during the period to junshi biosciences | ||||||||||||||||||||||||||||||||||||||||||||||
stock issued under optional stock purchase agreement | ||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents acquired from surface acquisition | 0 | |||||||||||||||||||||||||||||||||||||||||||||
milestone based license fee payment to junshi biosciences | 0 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from 2029 term loan, net of debt discount & issuance costs | -141,000 | |||||||||||||||||||||||||||||||||||||||||||||
repayment of 2027 term loans, premiums and exit fees | 0 | |||||||||||||||||||||||||||||||||||||||||||||
financing issuance costs in accounts payable | ||||||||||||||||||||||||||||||||||||||||||||||
gain on sale transaction | -153,647,000 | |||||||||||||||||||||||||||||||||||||||||||||
cash received from sale transaction | 187,823,000 | |||||||||||||||||||||||||||||||||||||||||||||
write-off of prepaid manufacturing services related to the termination of chs-2020 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
non-cash amortization of premium (accretion of discount) on marketable securities | ||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense from amortization of debt discount and issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
upfront and option payments to junshi biosciences | 0 | 0 | 70,000,000 | -35,000,000 | ||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment | -34,000 | 0 | -100,000 | -152,000 | -87,000 | -457,000 | -880,000 | -615,000 | -468,000 | -261,000 | -415,000 | -145,000 | -952,000 | -2,112,000 | -2,384,000 | -1,783,000 | -387,000 | -918,000 | -182,000 | -335,000 | -214,000 | -489,000 | -5,000 | -81,000 | -109,000 | -1,812,000 | -961,000 | -1,691,000 | -3,566,000 | -500,000 | -301,000 | -2,148,000 | -1,444,000 | -2,399,000 | -1,008,000 | -1,313,000 | -489,000 | |||||||||
proceeds from disposal of property and equipment | 76,000 | 151,000 | 440,000 | 178,000 | 8,000 | 0 | 0 | 167,000 | ||||||||||||||||||||||||||||||||||||||
milestone based license fee payments | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from 2027 term loans, net of debt discount & issuance costs | 0 | 49,489,000 | 0 | 191,190,000 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock to junshi biosciences, net of issuance costs | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
inventory write-offs | 1,475,000 | -347,000 | 3,241,000 | |||||||||||||||||||||||||||||||||||||||||||
non-cash accretion of discount on marketable securities | -601,000 | -895,000 | -1,339,000 | 186,000 | 260,000 | 370,000 | 279,000 | -52,000 | -23,000 | -15,000 | -73,000 | -54,000 | -32,000 | -155,000 | -70,000 | -44,000 | -6,000 | -30,000 | ||||||||||||||||||||||||||||
non-cash interest expense from amortization of debt discount & issuance costs | 583,000 | 573,000 | 656,000 | 800,000 | 954,000 | 981,000 | 3,696,000 | |||||||||||||||||||||||||||||||||||||||
option payment to shanghai junshi biosciences co., ltd. | ||||||||||||||||||||||||||||||||||||||||||||||
option payment to shanghai junshi biosciences ltd. | ||||||||||||||||||||||||||||||||||||||||||||||
taxes paid related to net share settlement of rsus | -305,000 | -2,781,000 | -123,000 | -321,000 | -642,000 | -2,658,000 | -23,000 | 0 | 0 | -1,730,000 | ||||||||||||||||||||||||||||||||||||
other upfront and milestone based license fee payments | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of 2026 convertible notes, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
purchase of capped call options related to 2026 convertible notes | ||||||||||||||||||||||||||||||||||||||||||||||
cash paid for income taxes | ||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of non-cash investing and financing activities | ||||||||||||||||||||||||||||||||||||||||||||||
purchase of property and equipment in accounts payable and accrued liabilities | ||||||||||||||||||||||||||||||||||||||||||||||
inventory reserves and write offs | ||||||||||||||||||||||||||||||||||||||||||||||
upfront and option payments to shanghai junshi biosciences ltd. | 35,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
write-off of inventory that did not meet acceptance criteria | -59,000 | |||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense from amortization of debt discount | 1,107,000 | 1,086,000 | 1,063,000 | 1,001,000 | 989,000 | 969,000 | 896,000 | 627,000 | 613,000 | 599,000 | 580,000 | 547,000 | 384,000 | 375,000 | 367,000 | 358,000 | 350,000 | 342,000 | 334,000 | 326,000 | 318,000 | 312,000 | 304,000 | 107,000 | ||||||||||||||||||||||
upfront license fee payment to junshi biosciences | 0 | 0 | 281,000,000 | -145,000,000 | ||||||||||||||||||||||||||||||||||||||||||
upfront and milestone based license fee payments | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from common stock offering, net of underwriters discounts, commissions and offering costs | 0 | 0 | 0 | 8,153,000 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of convertible notes due 2026, net of issuance costs | 0 | -674,000 | ||||||||||||||||||||||||||||||||||||||||||||
purchase of capped call options related to convertible notes due 2026 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from 2025 term loan, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
principal payments for finance lease obligations | ||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes in cash, cash equivalents and restricted cash | -106,000 | 59,000 | -93,000 | -136,000 | 138,000 | 117,000 | 226,000 | -13,000 | ||||||||||||||||||||||||||||||||||||||
right-of-use assets obtained in exchange for lease obligations related to operating leases | 0 | 0 | 0 | 0 | 1,388,000 | |||||||||||||||||||||||||||||||||||||||||
right-of-use assets obtained in exchange for lease obligations related to finance leases | 0 | 135,000 | 130,000 | 212,000 | 46,000 | 243,000 | 1,271,000 | 257,000 | ||||||||||||||||||||||||||||||||||||||
upfront and milestone based license fee payments to innovent | ||||||||||||||||||||||||||||||||||||||||||||||
other immaterial financing activities | -179,000 | -153,000 | -160,000 | |||||||||||||||||||||||||||||||||||||||||||
non-cash bonus payment settled in common stock | 0 | 0 | 1,498,000 | |||||||||||||||||||||||||||||||||||||||||||
upfront license fee payment to innovent | ||||||||||||||||||||||||||||||||||||||||||||||
write off of prepaid manufacturing services related to the termination of chs-2020 | 3,210,000 | |||||||||||||||||||||||||||||||||||||||||||||
upfront license fee payment to shanghai junshi biosciences ltd. | 145,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
accrued rebates, fees and reserve | -3,327,000 | 5,568,000 | 9,732,000 | 72,000 | 15,037,000 | 13,999,000 | 16,471,000 | |||||||||||||||||||||||||||||||||||||||
unpaid upfront license fee to innovent included in accounts payable as of march 31, 2020 | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
remeasurement of fair-value contingent consideration | 43,000 | -5,000 | 0 | 4,000 | -10,000 | -25,000 | -3,403,000 | 208,000 | 530,000 | 340,000 | -3,520,000 | 390,000 | ||||||||||||||||||||||||||||||||||
impairment of property and equipment | 94,000 | 0 | 254,000 | |||||||||||||||||||||||||||||||||||||||||||
excess and obsolete inventory | 0 | 0 | 0 | 410,000 | ||||||||||||||||||||||||||||||||||||||||||
other prepaid and current assets | -64,000 | 776,000 | 841,000 | -1,788,000 | -1,473,000 | 1,977,000 | 169,000 | -2,799,000 | ||||||||||||||||||||||||||||||||||||||
other assets, non-current | -1,171,000 | 661,000 | 152,000 | 0 | 0 | 2,000 | 86,000 | |||||||||||||||||||||||||||||||||||||||
accounts payable - related parties | 0 | 0 | -34,000 | -199,000 | 228,000 | -383,000 | -1,721,000 | 1,232,000 | -1,983,000 | 430,000 | -1,064,000 | -54,000 | -2,417,000 | 1,786,000 | 1,703,000 | -2,943,000 | ||||||||||||||||||||||||||||||
accrued and other liabilities | -35,000 | -2,240,000 | 5,626,000 | 2,135,000 | 970,000 | 8,099,000 | -710,000 | 2,027,000 | 8,200,000 | -1,042,000 | 456,000 | 1,229,000 | -6,271,000 | -4,831,000 | 4,773,000 | -113,000 | -4,735,000 | 6,263,000 | 5,564,000 | 1,944,000 | ||||||||||||||||||||||||||
lease liabilities | -1,445,000 | 326,000 | 169,000 | -489,000 | -420,000 | -570,000 | -514,000 | -506,000 | ||||||||||||||||||||||||||||||||||||||
other liabilities, non-current | 244,000 | 0 | 0 | 0 | -30,000 | -108,000 | -103,000 | -104,000 | -113,000 | -90,000 | 53,000 | 178,000 | 101,000 | 114,000 | 126,000 | -54,000 | -58,000 | 190,000 | 355,000 | -16,000 | -13,000 | -12,000 | ||||||||||||||||||||||||
purchase of non-controlling interest related to intekrin russia | 0 | |||||||||||||||||||||||||||||||||||||||||||||
purchase of non-controlling interest related to intekrin russia - related party | 0 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from term loan, net of issuance costs | 0 | -106,000 | 185,000 | 72,876,000 | ||||||||||||||||||||||||||||||||||||||||||
taxes paid related to net share settlement of bonus payout in rsus | 0 | 0 | 0 | -880,000 | ||||||||||||||||||||||||||||||||||||||||||
non-cash non-controlling interest reflected in additional paid in capital | 0 | |||||||||||||||||||||||||||||||||||||||||||||
common stock offering costs in accounts payable and accrued liabilities | ||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of property and equipment | 4,000 | 1,000 | ||||||||||||||||||||||||||||||||||||||||||||
non-cash manufacturing postponement fee settled in common stock | ||||||||||||||||||||||||||||||||||||||||||||||
upfront and milestone expense related to license and collaboration arrangements | ||||||||||||||||||||||||||||||||||||||||||||||
receivables from collaboration and license agreement | 0 | 0 | 26,000 | 1,833,000 | -1,440,000 | 0 | 776,000 | 365,000 | -1,020,000 | 914,000 | 561,000 | 402,000 | ||||||||||||||||||||||||||||||||||
deferred revenue | 0 | 0 | -1,394,000 | -168,000 | -223,000 | -86,080,000 | 5,432,000 | -12,365,000 | 32,677,000 | -7,174,000 | 12,303,000 | -5,512,000 | -6,037,000 | |||||||||||||||||||||||||||||||||
advance payments under license agreements | 0 | -80,000 | -50,000 | 230,000 | -360,000 | 1,330,000 | 0 | |||||||||||||||||||||||||||||||||||||||
upfront and milestone payments related to license and collaboration arrangements | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from private placement | 0 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuances of common stock upon exercise of stock options | 168,000 | 36,000 | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from purchase under the employee stock puchase plan | ||||||||||||||||||||||||||||||||||||||||||||||
purchase of non-controlling interest related to intekrin | ||||||||||||||||||||||||||||||||||||||||||||||
purchase of non-controlling interest related to intekrin - related party | ||||||||||||||||||||||||||||||||||||||||||||||
non-cash 2018 bonus payment settled in common stock | 0 | 0 | 1,350,000 | |||||||||||||||||||||||||||||||||||||||||||
right-of-use assets obtained in exchange for lease obligations | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from espp purchase | 827,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
accrued rebates, fees and returns | 11,945,000 | |||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, and restricted cash at beginning of period | 73,191,000 | 0 | 0 | 127,756,000 | ||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, and restricted cash at end of period | 82,350,000 | -28,803,000 | 47,984,000 | 82,856,000 | ||||||||||||||||||||||||||||||||||||||||||
provision for other receivables | 0 | 0 | 0 | -1,300,000 | ||||||||||||||||||||||||||||||||||||||||||
other prepaid assets | 760,000 | -641,000 | 291,000 | 606,000 | ||||||||||||||||||||||||||||||||||||||||||
other assets | 38,000 | 96,000 | -113,000 | 109,000 | 251,000 | 306,000 | 2,169,000 | 118,000 | -2,468,000 | -89,000 | 4,336,000 | -668,000 | -998,000 | -783,000 | -780,000 | -768,000 | -1,570,000 | |||||||||||||||||||||||||||||
accrued liabilities | ||||||||||||||||||||||||||||||||||||||||||||||
other liabilities | ||||||||||||||||||||||||||||||||||||||||||||||
contingent liability to collaborator | 0 | -76,755,000 | 22,755,000 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of convertible notes | 0 | 0 | 0 | 75,000,000 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of convertible notes - related parties | 0 | 0 | 0 | 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||
payments of convertible notes issuance costs | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of noncash investing and financing activities | ||||||||||||||||||||||||||||||||||||||||||||||
manufacturing services settled in common stock | ||||||||||||||||||||||||||||||||||||||||||||||
impairment on property and equipment | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales and maturities of investments in marketable securities | 14,000,000 | 14,500,000 | 45,000,000 | |||||||||||||||||||||||||||||||||||||||||||
proceeds from common stock offering, net of underwriters discounts and commissions | 0 | 99,017,000 | 1,781,000 | -68,017,000 | 75,000,000 | 0 | 124,866,000 | 0 | ||||||||||||||||||||||||||||||||||||||
payments of common stock offering issuance costs | -211,000 | -173,000 | -128,000 | -17,000 | -264,000 | -134,000 | -195,000 | -339,000 | ||||||||||||||||||||||||||||||||||||||
net (decrease) increase in cash, cash equivalents and restricted cash | ||||||||||||||||||||||||||||||||||||||||||||||
notes receivable | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
prepaid assets | 5,424,000 | 13,111,000 | -3,730,000 | 1,153,000 | -14,984,000 | -1,632,000 | 10,967,000 | 8,776,000 | -3,094,000 | -4,724,000 | -2,535,000 | |||||||||||||||||||||||||||||||||||
other assets - related party | 0 | |||||||||||||||||||||||||||||||||||||||||||||
increase in restricted cash | 0 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from follow-on offering, net of underwriters discounts and commissions | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
payments of initial public offering costs | 0 | 0 | 0 | -855,000 | ||||||||||||||||||||||||||||||||||||||||||
payments of follow-on offering costs and private placement | ||||||||||||||||||||||||||||||||||||||||||||||
payment of costs related to future offerings | ||||||||||||||||||||||||||||||||||||||||||||||
payments of common stock offering and private placement issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes in cash and cash equivalents | -7,000 | -70,000 | 122,000 | -165,000 | -271,000 | -45,000 | -35,000 | -47,000 | 82,000 | -21,000 | 175,000 | -152,000 | -465,000 | |||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | -8,646,000 | 62,205,000 | -51,572,000 | -23,000 | -34,730,000 | -61,239,000 | 41,358,000 | 21,332,000 | 4,535,000 | -52,397,000 | 90,952,000 | -35,256,000 | 49,517,000 | |||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of period | 0 | 0 | 0 | 124,947,000 | 0 | 0 | 0 | 158,226,000 | 0 | 0 | 0 | 150,392,000 | 0 | |||||||||||||||||||||||||||||||||
cash and cash equivalents at end of period | -8,646,000 | 62,205,000 | -51,572,000 | 124,924,000 | -34,730,000 | -61,239,000 | 41,358,000 | 179,558,000 | 4,535,000 | -52,397,000 | 90,952,000 | 115,136,000 | 49,517,000 | |||||||||||||||||||||||||||||||||
leasehold improvements allowance from landlord | ||||||||||||||||||||||||||||||||||||||||||||||
costs related to future offerings in accounts payable and accrued liabilities | ||||||||||||||||||||||||||||||||||||||||||||||
fair value of contingent consideration settled in common stock | ||||||||||||||||||||||||||||||||||||||||||||||
purchase of investments in marketable securities | -14,482,000 | -9,975,000 | -49,887,000 | |||||||||||||||||||||||||||||||||||||||||||
amortization of premium on marketable securities | -19,000 | |||||||||||||||||||||||||||||||||||||||||||||
remeasurement of convertible preferred stock warrant and embedded derivative liabilities | 526,000 | |||||||||||||||||||||||||||||||||||||||||||||
preferred stock issued in exchange for services | 0 | |||||||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of 2013 notes | ||||||||||||||||||||||||||||||||||||||||||||||
gain on (impairment of) property and equipment | ||||||||||||||||||||||||||||||||||||||||||||||
notes receivable from related parties | 0 | |||||||||||||||||||||||||||||||||||||||||||||
net cash acquired from acquisition of intekrin therapeutics inc. | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of convertible preferred stock, net of issuance costs | 0 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of convertible preferred stock upon exercise of warrants | 57,000 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from initial public offering, net of underwriters discounts and commissions | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from common stock offerings, net of underwriters discounts and commissions | ||||||||||||||||||||||||||||||||||||||||||||||
repurchase of restricted common stock | 0 | |||||||||||||||||||||||||||||||||||||||||||||
issuance of series b preferred stock for acquisition | ||||||||||||||||||||||||||||||||||||||||||||||
contingent consideration accrued in connection with acquisition | ||||||||||||||||||||||||||||||||||||||||||||||
conversion of 2013 notes and accrued interest into series c convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||
reclassification of fair value of convertible preferred stock warrants to preferred stock upon exercise | ||||||||||||||||||||||||||||||||||||||||||||||
initial public offering costs in accounts payable | ||||||||||||||||||||||||||||||||||||||||||||||
accrued expenses settled in common stock warrants | ||||||||||||||||||||||||||||||||||||||||||||||
accrued expenses settled in preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||
remeasurement of fair-value of contingent consideration | ||||||||||||||||||||||||||||||||||||||||||||||
other assets, related party | ||||||||||||||||||||||||||||||||||||||||||||||
payments of follow-on offering costs | -5,000 | -554,000 | -42,000 | |||||||||||||||||||||||||||||||||||||||||||
remeasurement of contingent consideration | 5,135,000 | 190,000 | 185,000 | 135,000 | 65,000 | 4,214,000 | 2,445,000 | |||||||||||||||||||||||||||||||||||||||
convertible notes issuance costs | -455,000 | |||||||||||||||||||||||||||||||||||||||||||||
fair value of warrants in excess of debt proceeds recognized at issuance | ||||||||||||||||||||||||||||||||||||||||||||||
fair value of embedded derivative in excess of debt proceeds recognized at issuance | ||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense and amortization of (receivable) debt discount | 0 | 1,000 | -17,000 | -22,000 | ||||||||||||||||||||||||||||||||||||||||||
accounts payable, related parties | ||||||||||||||||||||||||||||||||||||||||||||||
vesting of restricted common stock | ||||||||||||||||||||||||||||||||||||||||||||||
remeasurement of convertible preferred stock warrants | ||||||||||||||||||||||||||||||||||||||||||||||
receivables from related party | ||||||||||||||||||||||||||||||||||||||||||||||
other assets - non-current | 40,000 | 3,000 | -1,000 | |||||||||||||||||||||||||||||||||||||||||||
net cash acquired from acquisition of intekrin therapeutics, inc. | 0 | |||||||||||||||||||||||||||||||||||||||||||||
other current assets | 389,000 | |||||||||||||||||||||||||||||||||||||||||||||
advance payments under license agreements with related party | ||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense and amortization of debt discount | ||||||||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of 2013 and 2011 notes | ||||||||||||||||||||||||||||||||||||||||||||||
purchase of equipment in accounts payable | ||||||||||||||||||||||||||||||||||||||||||||||
issuance of convertible preferred stock in consideration for services | ||||||||||||||||||||||||||||||||||||||||||||||
conversion of 2011 notes and accrued interest into series b convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||
reacquisition of beneficial conversion feature as a result of the conversion of 2011 notes | ||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense | ||||||||||||||||||||||||||||||||||||||||||||||
receivables from related parties | ||||||||||||||||||||||||||||||||||||||||||||||
payment of costs related to initial public offering |